| For: | Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i5/1139.htm |
| Number | Citing Articles |
| 1 |
Lindsay Hahn, Ashton Beggs, Kristy Wahaib, Leela Kodali, Vanessa Kirkwood. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitis. American Journal of Health-System Pharmacy 2015; 72(15) doi: 10.2146/ajhp140449
|
| 2 |
Javier P. Gisbert, María Chaparro. Ustekinumab to treat Crohn's disease. Gastroenterología y Hepatología (English Edition) 2017; 40(10) doi: 10.1016/j.gastre.2017.08.003
|
| 3 |
Raewyn M. Poole. Vedolizumab: First Global Approval. Drugs 2014; 74(11) doi: 10.1007/s40265-014-0253-1
|
| 4 |
Diego Currò, Gianluca Ianiro, Silvia Pecere, Stefano Bibbò, Giovanni Cammarota. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology 2017; 174(11) doi: 10.1111/bph.13632
|
| 5 |
Ryan Marshall, Ian Taylor, Christopher Lahr, Thomas L. Abell, Ingrid Espinoza, Nitin K. Gupta, Christian R. Gomez. Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease. Clinical Medicine Insights: Gastroenterology 2015; 8 doi: 10.4137/CGast.S31779
|
| 6 |
Javier P. Gisbert, Eugeni Domènech. Vedolizumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2015; 38(5) doi: 10.1016/j.gastrohep.2014.12.003
|
| 7 |
M. V. Shapina, B. A. Nanaeva, A. V. Vardanyan. EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review. Koloproktologia 2019; 18(3(69)) doi: 10.33878/2073-7556-2019-18-3-119-130
|
| 8 |
Javier P. Gisbert, María Chaparro. Ustekinumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2017; 40(10) doi: 10.1016/j.gastrohep.2017.08.006
|